Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

Completed

• Conditions: ER/PR(+), Her2(-) Breast Cancer

• Registration Number: NCT02924584
• Lead Sponsor: Pfizer

Brief Summary

Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305 were registered as early breast cancer. With broadly application of aromatase inhibitors, hormonal-receptor-positive breast cancer patients can survive longer and longer. However, there is no prevalence of metastatic breast cancer can be available yet. NHIA database coverage is more than 90% population in Taiwan, thus it can be an appropriate surrogate of prevalence. In this retrospective database analysis, we will explore the real world experience on aromatase inhibitor use for breast cancer in Taiwan.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-10-03
• Study First Submitted QC: 2016-10-03
• Study First Posted: 2016-10-05
• Study Start: 2017-02-01
• Primary Completion: 2017-02-28
• Study Completion: 2018-04-30
• Status Verified: 2018-06
• Last Update Submitted: 2018-06-13
• Last Update Posted: 2018-06-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• hormonal receptor positive, human epidermal growth factor receptor 2 negative breast cancer

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clinical use of aromatase inhibitors in breast cancer	base line, up to 60 months	duration of treatment

Secondary Outcome Measures

Name	Time	Method
overall survival	base line, up to 60 months	The overall survival of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
treatment cost	base line, up to 60 months	The treatment cost of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
prevalence	base line up to 60 months	The prevalence of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
dose exposure	base line, up to 60 months	The dosage pattern of breast cancer with positive hormonal receptors with routine practice in Taiwan.

Trial Locations

Locations (1)

National Cheng Kung University; 🇨🇳 Tainan City, Taiwan